WATER IV Prostate Cancer

Not Applicable

Recruiting

• Conditions: Localized Prostate Cancer

• Registration Number: NCT06651632
• Lead Sponsor: PROCEPT BioRobotics

Brief Summary

This is a multicenter, prospective, randomized clinical trial that aims to assess the safety and efficacy of Aquablation Therapy in men with low-risk to intermediate to high-risk localized prostate cancer who are candidates for, or have opted for, prostatectomy. Participants will be randomized to either Aquablation Therapy or radical prostatectomy and followed up to 10 years.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-10-18
• Study First Submitted QC: 2024-10-18
• Study First Posted: 2024-10-22
• Status Verified: 2025-02
• Study Start: 2025-02-03
• Last Update Submitted: 2025-04-01
• Last Update Posted: 2025-04-03
• Primary Completion: 2027-07
• Study Completion: 2037-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Male
• Target Recruitment: 280

Inclusion Criteria

1. Biological male with age ≥ 45 years at the time of consent
2. Biopsy positive Grade Group 1-3 prostate cancer
3. Are candidates for prostatectomy or, in the case of GG1 disease, have already selected a radical therapy as their treatment.
4. Clinical Stage ≤ T2c
5. PSA ≤ 20 ng/ml
6. Prostate volume ≥25 ml

Exclusion Criteria

1. Any prior or current local or systemic treatment for prostate cancer, including but not limited to surgery, radiation therapy (external or brachytherapy), tissue ablation, hormone therapy or chemotherapy.
2. Patients with previous surgical or minimally invasive treatment of benign prostatic hyperplasia within the prior 3 months of study treatment.
3. Evidence of lymph node, bone metastasis, extracapsular extension or seminal vesicle invasion.
4. Patient is unwilling to accept a blood transfusion if required.
5. Any condition or history of illness or surgery that may pose an additional risk to patients undergoing the Aquablation or radical prostatectomy procedure such as:

5a. Medical conditions that preclude the use of anesthesia; 5b. Any condition or history of active rectal inflammatory bowel disease or other factors which might increase the risk of rectal injury (i.e. fistula formation); 5c. Patient is unable to stop anticoagulants or antiplatelet agents prior to study treatment per standard of care; 5d. Any other condition or history of infection, illness or surgery that in the opinion of the investigator might affect the outcome of the study procedure, study conduct, and study results; or pose additional risks to the patient (e.g., other cancer, active urethral stricture disease).

6. Patients who are unable to provide informed consent due to cognitive impairment, legal status (such as incarceration), or other factors limiting autonomy or unwilling or unable to follow study instructions including randomization and complete all required study visits through 10 years. This includes individuals with severe cognitive disabilities, those under legal guardianship, or those currently incarcerated.

7. Patient currently participating in other studies unless approved by Sponsor in writing.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Rate of pad use for urinary incontinence	6 Months
Rate of erectile dysfunction	6 Months

Secondary Outcome Measures

Name	Time	Method
Rate of pad use for urinary incontinence	3 Months
Rate of erectile dysfunction	3 Months
Stable or improved Grade Group at 1 year compared to baseline (Aquablation arm only)	1 Year

Trial Locations

Locations (39)

University of Miami; 🇺🇸 Miami, Florida, United States

Ochsner Clinic Foundation; 🇺🇸 New Orleans, Louisiana, United States

MUSC; 🇺🇸 Charleston, South Carolina, United States

Hampshire Hospitals NHS Foundation Trust; 🇬🇧 Basingstoke, Hamsphire, United Kingdom

University of Hertfordshire; 🇬🇧 Hatfield, Hertfordshire, United Kingdom

Arizona State Urological Institute; 🇺🇸 Chandler, Arizona, United States

East Valley Urology Center; 🇺🇸 Mesa, Arizona, United States

University of Southern California; 🇺🇸 Los Angeles, California, United States

Boulder Medical Center; 🇺🇸 Boulder, Colorado, United States

Advanced Research; 🇺🇸 Delray Beach, Florida, United States

Florida Urology Partners; 🇺🇸 Tampa, Florida, United States

Georgia Urology; 🇺🇸 Atlanta, Georgia, United States

University of Chicago; 🇺🇸 Chicago, Illinois, United States

Endeavor Health; 🇺🇸 Glenview, Illinois, United States

University of Kansas Medical Center; 🇺🇸 Kansas City, Kansas, United States

Kansas City Urology Care; 🇺🇸 North Kansas City, Missouri, United States

Kearney Urology Center; 🇺🇸 Kearney, Nebraska, United States

Adult & Pediatric Urology; 🇺🇸 Omaha, Nebraska, United States

Hackensack University Medical Center; 🇺🇸 Hackensack, New Jersey, United States

Solaris Health; 🇺🇸 New York, New York, United States

Icahn School of Medicine at Mount Sinai; 🇺🇸 New York, New York, United States

Cleveland Clinic Foundation; 🇺🇸 Cleveland, Ohio, United States

Fox Chase Cancer Center; 🇺🇸 Philadelphia, Pennsylvania, United States

Urology Associates PC; 🇺🇸 Nashville, Tennessee, United States

Urology Austin; 🇺🇸 Austin, Texas, United States

Urology Clinics of North Texas; 🇺🇸 Dallas, Texas, United States

Potomac Urology; 🇺🇸 Alexandria, Virginia, United States

Swedish Medical Center; 🇺🇸 Seattle, Washington, United States

Advocate Aurora Research Institute; 🇺🇸 Sheboygan, Wisconsin, United States

University of Toronto; 🇨🇦 Toronto, Ontario, Canada

Centre Hospitalier de l'Université de Montréal; 🇨🇦 Montréal, Quebec, Canada

Clinique Pasteur; 🇫🇷 Toulouse, France

Universitätsklinikum OWL der Universität Bielefeld; 🇩🇪 Bielefeld, Germany

Chinese University of Hong Kong; 🇭🇰 Shatin, Hong Kong

Hospital Cruz Vermelha; 🇵🇹 Lisbon, Portugal

National Taiwan University Hospital; 🇨🇳 Taipei, Taiwan

Norfolk & Norwich University Hospital; 🇬🇧 Colney, Norwich, United Kingdom

Guy's Hospital; 🇬🇧 London, United Kingdom

The Royal Marsden Hospital; 🇬🇧 London, United Kingdom